Evaxion Biotech A/S
EVAX
$1.65
$0.063.77%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 73.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 73.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 73.00K | -- | -- |
| SG&A Expenses | -- | -- | 10.35M | 10.67M | 10.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 22.27M | 24.36M | 24.36M |
| Operating Income | -- | -- | -22.20M | -24.36M | -24.36M |
| Income Before Tax | -- | -- | -22.92M | -25.26M | -25.26M |
| Income Tax Expenses | -- | -- | -790.00K | -786.00K | -786.00K |
| Earnings from Continuing Operations | -- | -- | -22.13 | -24.47 | -24.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -22.13M | -24.47M | -24.47M |
| EBIT | -- | -- | -22.20M | -24.36M | -24.36M |
| EBITDA | -- | -- | -21.67M | -23.83M | -23.83M |
| EPS Basic | -- | -- | -2.04K | -2.37K | -94.74 |
| Normalized Basic EPS | -- | -- | -18.62 | -22.75 | -4.55 |
| EPS Diluted | -- | -- | -2.04K | -2.37K | -94.74 |
| Normalized Diluted EPS | -- | -- | -18.62 | -22.75 | -4.55 |
| Average Basic Shares Outstanding | -- | -- | 2.18M | 2.08M | 10.40M |
| Average Diluted Shares Outstanding | -- | -- | 43.60K | 41.50K | 1.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |